CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $11.98M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -2.48: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
269.99MUSDvs all stocks (USD)
Revenue (TTM)
11.98MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.5550xvs all stocks
52-Week Change
174.79%vs all stocks
Market Capitalization
269.99MUSDvs all stocks (USD)
Enterprise Value
232.14MUSDvs all stocks (USD)
Forward P/E
-4.28xvs Biotechnology peers
Price to Sales (TTM)
22.53xvs Biotechnology peers
Enterprise to Revenue
19.37xvs Biotechnology peers
Enterprise to EBITDA
-5.40xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-665.92%vs Biotechnology peers
Return on Assets (TTM)
-46.79%vs Biotechnology peers
Revenue (TTM)
11.98MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1590USDUpdated Jul 19, 2026Quarterly Revenue Growth
-50.60%vs Biotechnology peers
Gross Profit (TTM)
-21.45MUSDvs all stocks (USD)
EBITDA (TTM)
-42.98MUSDvs all stocks (USD)
Net Income (TTM)
-106.93MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-50.64%vs Biotechnology peers
Operating Cash Flow (TTM)
-38.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.27MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
14.20MUSDFY2025 · Dec 31, 2025Operating Income
-38.60MUSDvs all stocks (USD)
Pre-tax Income
-49.59MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-49.59MUSDFY2025 · Dec 31, 2025EBIT
-48.13MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-36.56MUSDFY2025 · Dec 31, 2025Research & Development
30.81MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
21.98MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.47MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8000USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
62.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
62.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-49.59MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-42.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
45.09MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-49.59MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
53.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.52MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.61MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
7.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-152.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.30MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
33.33MUSDFY2025 · Dec 31, 2025Shares Outstanding
71.40MSharesUpdated Jul 19, 2026Float Shares
63.68MSharesUpdated Jul 19, 2026Shares Short
8.23MSharesUpdated Jul 19, 2026Short Ratio
6.93daysvs all stocks
Short % of Shares Outstanding
10.48%vs all stocks
% Held by Insiders
11.06%vs all stocks
% Held by Institutions
55.14%vs all stocks
Total Cash (MRQ)
59.96MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7370USDUpdated Jul 19, 2026Total Debt (MRQ)
1.20MUSDvs all stocks (USD)
Current Ratio (MRQ)
7.13xvs Biotechnology peers
Book Value per Share (MRQ)
-0.6420USDUpdated Jul 19, 2026Total Assets
50.24MUSDvs all stocks (USD)
Total Current Assets
50.04MUSDFY2025 · Dec 31, 2025Total Liabilities
34.90MUSDFY2025 · Dec 31, 2025Total Non-current Assets
199.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
27.11MUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.78MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Receivable
2.00MUSDFY2025 · Dec 31, 2025Accounts Payable
3.29MUSDFY2025 · Dec 31, 2025Long-term Debt
1.13MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-188.59MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
15.35MUSDvs all stocks (USD)
52-Week Low
1.04USDUpdated Jul 19, 202652-Week High
5.81USDUpdated Jul 19, 202652-Week Change
174.79%vs all stocks
Beta
0.5550xvs all stocks
50-Day MA
4.20USDUpdated Jul 19, 2026200-Day MA
3.39USDUpdated Jul 19, 2026Avg 10-Day Volume
829.52KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.07MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.31USDUpdated Jul 19, 2026Other Income / Expense
-9.53MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 22.53Revenue Growth YoY: -0.51
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 7.13Altman Z-Score: -2.48
Financial Health
Altman Z-Score -2.48: distress zoneCritical
Altman Z-Score: -2.48
High structural barrier to entryNotable
Barrier to Entry: 68.24
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $11.98M, lower than 95% of all stocks globallySignificant
Revenue (USD): 11,983,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Eos Energy Enterprises Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC